Literature DB >> 34657445

First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension.

Horng H Chen1, Siu-Hin Wan2, Seethalakshmi R Iyer1, Valentina Cannone3, S Jeson Sangaralingham1, Joel Nuetel4, John C Burnett1.   

Abstract

[Figure: see text].

Entities:  

Keywords:  aldosterone; blood pressure; cardiovascular disease; guanylyl cyclase; natriuresis

Mesh：

Substances：

Year:  2021        PMID： 34657445      PMCID： PMC8666702          DOI： 10.1161/HYPERTENSIONAHA.121.17159

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


  36 in total

1.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

2.  Effect of atrial peptides on aldosterone production.

Authors:  K Atarashi; P J Mulrow; R Franco-Saenz
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 3.  Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.

Authors:  Yang Chen; John C Burnett
Journal:  Clin Chem       Date:  2016-11-15       Impact factor: 8.327

4.  Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.

Authors:  Yang Chen; Jacob J Schaefer; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; S Jeson Sangaralingham; Horng H Chen; Margaret M Redfield; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-02-05       Impact factor: 3.619

5.  Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor.

Authors:  Lasse H Hansen; Thomas Daugbjerg Madsen; Christoffer K Goth; Henrik Clausen; Yang Chen; Nina Dzhoyashvili; Seethalakshmi R Iyer; S Jeson Sangaralingham; John C Burnett; Jens F Rehfeld; Sergey Y Vakhrushev; Katrine T Schjoldager; Jens P Goetze
Journal:  J Biol Chem       Date:  2019-06-11       Impact factor: 5.157

6.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A.

Authors:  P M Oliver; J E Fox; R Kim; H A Rockman; H S Kim; R L Reddick; K N Pandey; S L Milgram; O Smithies; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

7.  Sympathoinhibitory effects of atrial natriuretic factor in normal humans.

Authors:  J S Floras
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

Review 8.  Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation.

Authors:  Curt D Sigmund; Robert M Carey; Lawrence J Appel; Donna K Arnett; Hayden B Bosworth; William C Cushman; Zorina S Galis; Melissa Green Parker; John E Hall; David G Harrison; Alicia A McDonough; Holly L Nicastro; Suzanne Oparil; John W Osborn; Mohan K Raizada; Jacqueline D Wright; Young S Oh
Journal:  Hypertension       Date:  2020-02-17       Impact factor: 10.190

Review 9.  Cardiac natriuretic peptides.

Authors:  Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold
Journal:  Nat Rev Cardiol       Date:  2020-05-22       Impact factor: 32.419

Review 10.  Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development.

Authors:  Speranza Rubattu; Maurizio Forte; Simona Marchitti; Massimo Volpe
Journal:  Int J Mol Sci       Date:  2019-02-13       Impact factor: 5.923
View more
  6 in total

1.  MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice.

Authors:  Yang Chen; Seethalakshmi R Iyer; Viacheslav O Nikolaev; Fabio Naro; Manuela Pellegrini; Silvia Cardarelli; Xiao Ma; Hon-Chi Lee; John C Burnett
Journal:  Hypertension       Date:  2022-06-08       Impact factor: 9.897

2.  Purification, characterization, and preliminary serial crystallography diffraction advances structure determination of full-length human particulate guanylyl cyclase A receptor.

Authors:  Shangji Zhang; Debra T Hansen; Jose M Martin-Garcia; James D Zook; Shuchong Pan; Felicia M Craciunescu; John C Burnett; Petra Fromme
Journal:  Sci Rep       Date:  2022-07-12       Impact factor: 4.996

3.  MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.

Authors:  Nina A Dzhoyashvili; Seethalakshmi R Iyer; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 10.190

4.  Effects of elevation of ANP and its deficiency on cardiorenal function.

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Kristen Winsor; Gregory R Blass; Denisha R Spires; Elizaveta Sarsenova; Iuliia Polina; Adrian Zietara; Mark Paterson; Alison J Kriegel; Alexander Staruschenko
Journal:  JCI Insight       Date:  2022-05-09

5.  Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension.

Authors:  Valentina Cannone; John C Burnett
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

Review 6.  Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.

Authors:  Tomoko Ichiki; Atsushi Jinno; Yoshihisa Tsuji
Journal:  Biology (Basel)       Date:  2022-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.